ICON Opens Purpose-Built, Hospital Based Translational Medicine Unit in Manchester
16 Juillet 2010 - 2:25PM
Business Wire
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider
of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced the
official opening of a purpose-built clinical pharmacology unit
within the Central Manchester University Hospitals Foundation Trust
(CMFT) campus in Manchester, UK. Initial studies in the unit
utilising translational medicine methodologies to expedite drug
development projects began in June, and already 110 volunteers have
participated in studies there.
The two-floor, 34-bed hospital-based unit brings ICON’s Phase I
global bed capacity to over 280 beds, and includes a sample
handling laboratory, 24-hour medical cover, local GMP pharmacy,
contiguous access to the Accident and Emergency department at the
Manchester Royal Infirmary and local bioanalytical support. The
unit also features four fully environmentally controlled
pharmacodynamic testing suites where ICON continues its
industry-leading work modelling complex pathologies to identify
early efficacy signals of compounds in clinical areas such as
Neuropathic Pain, Anxiety and Cognitive Degeneration.
Alan Morgan, ICON Group President – Early Clinical Research,
commented: “ICON has conducted clinical pharmacology studies in
Manchester for over 25 years, and the opening of this translational
medicine unit further demonstrates our commitment to streamlining
the process that guides new compounds through the early phases of
development into treatments that improve human health. Our
collaborative relationship with the CMFT, and the location of the
new unit on one of the largest teaching hospitals in the UK,
facilitates unrivalled access to the expertise, specialist
procedures and patient populations necessary to bring life saving
medicines to market faster.”
CMFT is a member of the Manchester Academic Health Science
Centre (MAHSC), which is one of only five such sites in the UK
designated by the Department of Health as a centre of excellence in
applying health research and education into healthcare. Through the
collaboration, ICON shares expertise with academic and medical
communities of this network and has access to the facilities of
other NHS members and the University of Manchester.
Notes to
Editors:
About ICON plc:
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
employs over 7,300 employees, operating from 71 locations in 39
countries.
ICON/ICLR-F
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Août 2023 à Août 2024